Local NewsBusiness LONDON–(BUSINESS WIRE)–Jan 28, 2021– Quantzig, one of the world’s leading analytics solutions provider, announced the addition of new procurement analytics services to its advanced supply chain analytics portfolio. Quantzig’s procurement analytics capabilities cover various aspects of the supply chain, including- pricing, working capital optimization, compliance analysis, and supplier performance assessment. The main challenge for enterprises today is having access to procurement data but not being able to infuse insights into their procurement strategies. Quantzig’s procurement analytics solutions aim to address this need by helping businesses act on insights. Contact an analytics expert for more information. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210128005041/en/ Today’s competitive environment necessitates businesses of all sizes to act on data-driven insights to make crucial business decisions. Analytics has proven to help businesses in this regard by offering decision-makers, managers, and C-suite executives access to these insights, thereby saving time, reducing costs, optimizing process life cycles, and increasing productivity. Given the benefits of embedding analytics into business processes, the need for procurement analytics initially evolved from the desire to get a consolidated view on procurement spend. Today procurement analytics encompasses a vast portfolio of specialized analytics solutions, data dashboards, and data visualization and reporting solutions. Businesses can utilize procurement analytics to analyze, predict, and improve procurement and supply chain performance. Learn more about the role and business benefits of procurement analytics from our experts. How Can Quantzig’s Procurement Analytics Solutions Help You? While most procurement organizations have a common goal of creating a single source of truth through enhanced data visibility, they face unique challenges in achieving their goals. Traditionally, procurement analytics solutions focused on analyzing procurement spend and supplier performance, but today the focus is shifting towards automated and prescriptive decision making with a strong focus on innovation and technology implementation. Evidently, this shift is accelerated by the growing needs of procurement organizations facing digital transformations. Quantzig, through its unique offerings and customizable procurement analytics solutions, offers businesses relevant, timely insights that improve supply chain performance and productivity. Drawing on our expertise in the field of procurement, we focus on integrating the best practices to drive continuous process improvements in procurement. Request a FREE pilot to get started. Quantzig’s advanced procurement analytics capabilities empower businesses to perform sophisticated quantitative operations and draw actionable insights from data. A unique mix of domain expertise and industry knowledge sets us apart, making us the most preferred analytics service provider globally. Our procurement analytics solutions drive impactful outcomes by-Integrating multi-language and multi-currency data from disparate sourcesImplementing interactive dashboards and visually impactful reportsAnalyzing supplier performance and finding new opportunities to growLeveraging cutting-edge analytical technologies to support strategy creation and decision-making in dynamic markets With a huge clientele, which ranges from CEOs to BU heads to stakeholders of Fortune 500 companies, we have played an active part in improving business outcomes globally. Our expertise and domain knowledge also reflect the number of projects we’ve worked on and the results that have prompted businesses to engage with us on an ongoing basis, making us the most preferred analytics partner for leading businesses. We have a proven track record of helping businesses across North America, Europe, EMEA, and APAC leverage procurement analytics to drive better outcomes. Request a FREE proposal to gain detailed insights into our engagement policies. About Quantzig Quantzig is the world’s foremost full-service advanced analytics and business intelligence solution provider, turning clients’ complex, unstructured data into intelligent, actionable insights that enable them to solve complex business problems and inspire innovation, change, and growth. Over the past 16 years, our insights have helped over 120 clients spanning across industries and sectors like Pharmaceutical and Life Sciences, Retail and CPG, Food and Beverage, and more. We have successfully delivered 1500 in-depth solutions in areas like Marketing Analytics, Customer Analytics, Supply Chain Analytics, and more. For more information on our engagement policies and pricing plans, visit: https://www.quantzig.com/request-for-proposal View source version on businesswire.com:https://www.businesswire.com/news/home/20210128005041/en/ CONTACT: Quantzig Eva Sharma Marketing Manager US: +1 630 538 7144 UK: +44 208 629 1455 https://www.quantzig.com/contact-us KEYWORD: INDUSTRY KEYWORD: MARKETING CONSULTING COMMUNICATIONS PROFESSIONAL SERVICES SOURCE: Quantzig Copyright Business Wire 2021. PUB: 01/28/2021 09:15 AM/DISC: 01/28/2021 09:15 AM http://www.businesswire.com/news/home/20210128005041/en Pinterest Twitter Turning Procurement Data into Dollars with Procurement Analytics | Request a Free Pilot to Learn Why Global Leaders Prefer Quantzig WhatsApp Facebook Pinterest TAGS Twitter WhatsApp Facebook By Digital AIM Web Support – January 28, 2021 Previous articleVirios Therapeutics to Present at the BIO CEO & Investor ConferenceNext articleMenuDrive, the Leading Commission-Free Restaurant Online Ordering System, Announces a New VP of Engineering Digital AIM Web Support
The announcement by Oregon Health & Science University that scientists there had edited the genes of human embryos to remove the cause of a deadly disease has raised the prospect of a powerful new tool for physicians — as well as fears of a Pandora’s Box that could lead to “designer babies” and humans engineered for desirable traits such as strength or intelligence. Robert Truog is the Frances Glessner Lee Professor of Medical Ethics, Anaesthesiology, and Pediatrics, and the director of Harvard Medical School’s Center for Bioethics. In a Gazette Q&A he shared his thoughts on the debate the breakthrough set off. GAZETTE: Researchers said they cured a relatively common and potentially deadly genetic disease, hypertrophic cardiomyopathy. Why is this not uniformly good news? What’s the big fear?TRUOG: Many people believe that there’s something sacred about the human genome and messing with it feels like playing God. In their view, we shouldn’t be interfering with the natural order of things. These are serious concerns and they definitely need to be addressed. But the idea that we could choose not to do this, I think, is impossible. If we were to decide not to pursue human genome editing in the United States, it would still take place everywhere else in the world.We have an opportunity here for a leadership role — to show how, with good oversight, we can do research in controversial areas in ways that are careful, well-considered, and cautious. The National Academy of Sciences’ report captured this extremely well. They did not recommend a prohibition on human genome editing, but they did stipulate a number of considerations that needed to go into any proposals about doing this kind of work.GAZETTE: What were the most important of those considerations, to your mind?TRUOG: One is that it concern only severe and life-threatening diseases, such as hypertrophic cardiomyopathy, which the Oregon researchers were looking at. We’re not looking at “enhancements” here, we’re not looking at how to make normal people better, we’re looking at those rare situations where the genes really are life-threatening. If you have one of these genes, you’re likely going to die. And the work right now is focusing on that small set of conditions where that’s true.Another one of the conditions that the National Academy of Sciences placed is that there be no alternatives. And for most couples who are considering having a child and where they carry one of these life-threatening genes, we have preimplantation genetic diagnosis, or PGD, which is a really good alternative. Since that’s a well-developed technology with a good safety record, that would be something that would be considered first.It would only be for a really small number of couples who wanted to have a genetically-related child who were incapable of producing disease-free embryos that this kind of technology would make any sense. This isn’t about “designer babies.” This is about offering a very small number of couples their only chance to have a baby that is genetically connected to them that doesn’t have a lethal condition.GAZETTE: Is this analogous to the ethical concerns raised with in vitro fertilization back when that infertility treatment first arose? Is this the beginning of a societal discussion that we need to have?TRUOG: Yes, I think that’s actually a very good analogy. There were many concerns raised around IVF and test-tube babies when that was developed, and I think we had a good societal discussion about it. While issues certainly remain, I think that has become a fairly accepted method for couples who can’t otherwise have a child to be able to have a genetically-related offspring.GAZETTE: Are you troubled at all by the fact that, should a couple have a genetically engineered child, that change would then be passed on generation after generation?TRUOG: It’s hard to imagine an objection to the fact that a non-diseased gene would be passed to the next generation. I think the concerns would be more about off-target changes in the person that may not even be recognized that could then be passed on to future generations. I think that this is a concern and I know that a lot of the research will focus very much on the rates of off-target effects and how to control them and how to assure that they’re within acceptable limits.That being said, there’s — in nature — all sorts of alterations to the genome made from one generation to the next that we have no control over, we can’t predict. The fact that, in this case, we would be creating these alterations gives us a certain responsibility for monitoring them and being careful, but it’s not that unexpected changes in the genome don’t occur quite regularly.GAZETTE: Do you have any particular concerns or were you troubled at all by this research?TRUOG: I’m really pleased to see this proceeding in a very controlled, thoughtful way. I think my concerns would be twofold. One, that rogue scientists in another country would begin to develop this in ways that we would agree are not socially acceptable. For example, moving quickly into enhancement-type technologies. That’s another reason why we in the United States would be foolish to put our heads in the sand. We need to take a leadership role here and be a model for the rest of the world.Number two is what happened with a lot of the stem cell research, which is where irresponsible clinicians hang out a shingle and make ridiculous and unsubstantiated claims about diseases that they can treat and, in a sense, lure vulnerable patients and perhaps couples into getting therapy that could potentially be quite dangerous.